Fluorinated Curcuminoid Compounds for Enhanced Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of curcumin-based anti-cancer drugs is hindered by curcumin's poor solubility, low absorption, low bioavailability, and rapid metabolism, despite its potential health benefits, due to unfavorable bio-physicochemical features.
Innovation Solution
Synthesis of novel CUR— and CUR—BF2 compounds with monocyclic aromatic and bicyclic-heteroaromatic lateral rings, incorporating fluorine, OCF3, and SCF3 groups to enhance polarity and lipophilicity, along with alpha-carbonyl-fluorinated analogs and pyrazole/isoxazole derivatives, which are designed to improve metabolic stability and binding affinity to cancer-related proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcumin is used as an anti-cancer agent, then it exhibits anti-proliferative and apoptotic activity against cancer cells, but it suffers from poor solubility, low absorption, low bioavailability, and rapid metabolism
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of curcumin through fluorine substitution at the alpha-carbonyl position and introducing various aryl groups with different substituents (F, OCF3, CF3, SCF3). These structural parameter changes improve lipophilicity and metabolic stability while maintaining anti-cancer activity, directly addressing the bioavailability problem
Solution Approach 2:
The invention creates composite molecular structures by combining the curcumin core with fluorinated alpha-carbonyl groups and diverse aryl substituents. This composite approach generates a library of analogs with optimized properties, achieving both improved bioavailability and maintained anti-cancer efficacy
2Quantity of substance
If curcumin structure is modified to improve bioavailability, then solubility and absorption may improve, but binding affinity to target proteins may be reduced
Solution Approach 1:
The patent applies local quality by introducing fluorine substitution specifically at the alpha-carbonyl position rather than modifying the entire curcumin structure. This localized modification improves metabolic stability and lipophilicity while preserving the central beta-keto-enolic moiety that is critical for protein binding, thus maintaining binding affinity
Solution Approach 2:
The invention systematically varies substituents on the aryl groups (F, OCF3, CF3, SCF3) to optimize the balance between bioavailability and binding affinity. These parameter changes allow fine-tuning of lipophilicity and metabolic stability without compromising the pharmacophore features necessary for target protein interaction
Data Source
AI summary
Novel CUR— and CUR—BF2 compounds as well as novel bis and mono-NSAID/CUR—BF2 and NSAID/CUR hybrids exhibiting anti-tumor properties are presented. CUR compounds bearing fluorinated moieties with selective fluorine introduction into the α-carbonyl moiety as well as CUR—BF2 adducts and CURs with diverse substitution patterns in the phenyl rings including fluorinated substituents (SCF3, OCF3, and F) and/or bulky activating groups (OMe, OAc, and OBz) are presented. Fluorinated aryl-pyrazoles and isoxazoles as well as novel CUR and CUR—BF2 compounds with monocyclic aromatic and bicyclic-heteroaromatic lateral rings, bearing fluorine(s), OCF3, CF3, and SCF3 groups, and their alpha-carbonyl-fluorinated analogs, as well as their pyrazole and isoxazole derivatives are presented. The CUR-pyrazoles embody analogs that are fluorinated at the phenyl-pyrazole moiety. The hybrids, compounds, and their derivatives exhibited exceptional cytotoxic and anti-proliferative activity against several cancer cell-lines. The hybrid NSAID/CUR compounds also exhibited exceptional anti-inflammatory activity over NSAID or curcumin alone.